The identification of compounds may be promising candidates for drug development research has become easier to follow by the Walter and Eliza Hall Institute of Medical Chemistry group.Dr Jonathan Bael and Dr. Georgina Holloway developed a series of filters that can be used to remove these molecules can come in many false positives when testing a library of chemical compounds that may be useful in drug development.

high-performance chemical detection (CTH) seeks to identify chemical compounds that interact with a target protein and therefore potential candidates for drug development. There may be 30,000 to one million compounds in a library and screening thousands of compounds can be identified as “positive” interaction with a protein of interest. These compounds become the subject of time medicinal chemistry that scientists are trying to perfect for the entry into the drug development pipeline.

Dr. Bael, said 10 percent of the compounds at any screening library available in the market may appear as false positives, which could lose hundreds of hours of the scientists who do the work of medicinal chemistry to optimize these molecules.

(more…)

A team of scientists including the University of Utah, researchers found that the binding of a potent inhibitor of hepatitis C virus (HCV) for the virus’s genetic material causes a significant change in conformation that can adversely affect the ability of the virus to replicated. This discovery, published in the March 29 edition of the first acts of the National Academy of Sciences, offers a new potential target for the design of the structure on the basis of new treatments for hepatitis C.

Hepatitis C is a major public health problem affecting 170 million people worldwide, with 2 to 3 million new cases diagnosed each year. In the U.S., HCV infection is the leading cause of liver cancer and liver transplantation, killing about 10,000 people each year. Currently, the most effective treatment for hepatitis C is an agent called pegylated interferon, which is often associated with an antiviral drug called ribavirin.

“The available therapies for hepatitis C have limited effectiveness, with less than 50 percent of an answer,” said Darrell R. Davis, Ph.D., lead author and professor and interim chair of medical chemistry and biochemistry professor at the University of Utah. “However, small molecules that inhibit viral replication have been reported and represent potential opportunities for new HCV treatments more effective.”

(more…)